EPO and small cell lung carcinoma: A total of 130 non-anaemic SCLC patients were randomized to receive no additional treatment (n = 44), epoetin α 150 IU kg−1 subcutaneously (s.c.)three times a week (n = 42) or 300 IU kg−1 s.c. three times a week (n = 44).